FindTrial
Sign In

The efficacy of immune checkpoint inhibitors in endometrial cancer

A multicenter retrospective study on the efficacy and prognosis of immune checkpoint inhibitors for undifferentiated/dedifferentiated endometrial cancer in the real world

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105073
Enrollment
Unknown
Registered
2025-06-27
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Undifferentiated/dedifferentiated endometrial cancer

Interventions

Observation group (immune checkpoint inhibitor treatment group):None

Sponsors

Chongqing University Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age>=18 years; 2. Histopathologically confirmed endometrial undifferentiated/dedifferentiated carcinoma; 3. Have complete admission or outpatient treatment information; 4. There are molecular typing test results or 10 tissue paraffin sections can be provided.

Exclusion criteria

Exclusion criteria: 1. Metastasis of the uterine corpus from malignant tumors in other sites; 2. Patients with neuropsychiatric disorders, patients or family members who are unable to understand the conditions and objectives of this study; 3. Patients lacking most of the clinical data or follow-up records.

Design outcomes

Primary

MeasureTime frame
Survival indicators (OS, PFS);—

Secondary

MeasureTime frame
PD-L1 expression;TCGA molecular subtyping of endometrial cancer;SWI/SNF expression;—

Countries

China

Contacts

Public ContactXingtao Long

Chongqing University Cancer Hospital

longxingtao2009@163.com+86 23 65075696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026